Get started

NIHR Manchester Clinical Research Facility

Alternate names: Manchester CRF, Manchester Clinical Research Facility, Manchester Clinical Research Facility (CRF Clinic), Manchester Clinical Research Facility (CRF), ManchesterCRF, NIHR Manchester CRF
ROR: 02e706q76
OpenAlex ID: I4405271435
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
2020 · Stephen R. D. Johnston, Nadia Harbeck, et al. · Journal of Clinical Oncology · 1,090
PDF
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
2018 · Andrew Tutt, Holly Tovey, et al. · Nature Medicine · 940
PDF
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
2021 · D. Miles, J. Gligorov, et al. · Annals of Oncology · 765
PDF
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
2020 · Franck Morschhauser, Hervé Tilly, et al. · The Lancet Oncology · 649
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
2021 · Paolo F Caimi, Weiyun Ai, et al. · The Lancet Oncology · 470
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
2020 · Nicholas C Turner, Belinda Kingston, et al. · The Lancet Oncology · 398
PDF
Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection
2021 · Jianmin Zuo, Alexander C. Dowell, et al. · Nature Immunology · 386
PDF
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
2019 · Helena M Earl, Louise Hiller, et al. · The Lancet · 297
PDF
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial
2019 · Roy S Herbst, Hendrik-Tobias Arkenau, et al. · The Lancet Oncology · 270
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
2020 · Sara M Tolaney, Andrew M Wardley, et al. · The Lancet Oncology · 263
Swept-Source Optical Coherence Tomography Angio™ (Topcon Corp, Japan): Technology Review
2016 · Paulo E. Stanga, Emmanouil Tsamis, et al. · Developments in ophthalmology · 163
Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
2019 · Françoise Rothé, Maria Joao Silva, et al. · Clinical Cancer Research · 130
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
2023 · Philippe Armand, Pier Luigi Zinzani, et al. · Blood · 124
PDF
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
2019 · T. Bachelot, E. Ciruelos, et al. · Annals of Oncology · 119
PDF
Corneal confocal microscopy identifies corneal nerve fibre loss and increased dendritic cells in patients with long COVID
2021 · Gulfidan Bitirgen, Celalettin Korkmaz, et al. · British Journal of Ophthalmology · 112
PDF
Corneal confocal microscopy detects small‐fiber neuropathy in Charcot–Marie–Tooth disease type 1A patients
2012 · Mitra Tavakoli, Andy Marshall, et al. · Muscle & Nerve · 110
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
2021 · D. Miles, E. Ciruelos, et al. · Annals of Oncology · 103
PDF
LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)
2020 · D.W. Miles, J. Gligorov, et al. · Annals of Oncology · 102
Greater corneal nerve loss at the inferior whorl is related to the presence of diabetic neuropathy and painful diabetic neuropathy
2018 · Alise Kalteniece, Maryam Ferdousi, et al. · Scientific Reports · 102
PDF
Child and Parental Perspectives on Communication and Decision Making in Pediatric CKD: A Focus Group Study
2018 · Talia Gutman, Camilla S. Hanson, et al. · American Journal of Kidney Diseases · 101
Genomic profile of advanced breast cancer in circulating tumour DNA
2021 · Belinda Kingston, Rosalind J. Cutts, et al. · Nature Communications · 99
PDF
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study
2021 · Mehdi Hamadani, Graham P Collins, et al. · The Lancet Haematology · 93
Trial Forge Guidance 3: randomised trials and how to recruit and retain individuals from ethnic minority groups—practical guidance to support better practice
2022 · Shoba Dawson, Katie Banister, et al. · Trials · 88
PDF
Evidence for an enduring ischaemic penumbra following central retinal artery occlusion, with implications for fibrinolytic therapy
2015 · David McLeod, Stephen Beatty · Progress in Retinal and Eye Research · 86
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial
2022 · Saye H Khoo, Richard FitzGerald, et al. · The Lancet Infectious Diseases · 83
PDF
Works count: 193
Citation count: 17,050
Year
Topic
Type